Ajinomoto And Kyoto Team Develop iPS Cell Culture Medium StemFit
This article was originally published in PharmAsia News
Ajinomoto and Kyoto University’s Center for iPS Cell Research and Application have developed StemFit, a new iPS cell medium made up of a balance of amino acids, sugars, lipids, growth factors that does not contain animal/human-derived components
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.